Revvity (RVTY)
Supplies research tools, scientific software, and clinical diagnostics from discovery through screening.
Something off on this page? Send us feedback.
Supplies reagents, instruments, scientific software, laboratory services, and clinical testing workflows across Life Sciences and Diagnostics. Revenue is split roughly evenly between the segments, spanning research tools on one side and immunodiagnostics, reproductive health, and genomics on the other.
Operates through Life Sciences and Diagnostics. Life Sciences spans BioLegend reagents, assay technologies, imaging and automation instruments, Revvity Signals scientific software, and multi-omics services used in drug discovery and development.
Diagnostics provides reproductive-health and newborn-screening platforms, genomic testing, cord-blood banking through ViaCord, and EUROIMMUN and T-SPOT immunodiagnostics. Across both segments, the model pairs specialized consumables with instruments, software, laboratory services, and licensing for pharmaceutical and biotechnology companies, clinical laboratories, universities, and government customers.
Products reach customers through specialized sales teams and distributors across more than 160 countries. Clinical assays and screening systems depend on country-specific approvals and quality compliance, while some critical inputs come from limited or single suppliers. An agreed sale of the China immunodiagnostics business remains subject to closing and regulatory approval.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Target | Target: $120 | Target: $140 |
| Sep 4, 2026 | KeyBanc | Reiterate | Rating: —Target: $132 | Target: $165 |
| Sep 1, 2026 | RBC Capital | Initiate | Rating: —Target: — | Target: $135 |
| Jul 6, 2026 | Evercore ISI | Reiterate | Rating: —Target: $118 | Target: $125 |
| Jun 26, 2026 | Bernstein | Target | Target: $130 | Target: $115 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 5, 2026Cash & short-term investments $1.02B · Total debt $3.34B · Total assets $12.05B · Shareholders' equity $7.23B
- Revenue
- $729.7M
- Operating income
- $89.3M
- Net income
- $51.8M
HistoryDividendAnnual yieldUpcoming
| Institutions | ≈ 102.83% | 114.72M shares | |
|---|---|---|---|
| 554 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.47% | 522.0K shares | |
| 15 holders · as of Sep 18, 2026 | |||
| Strategic holders | 6.84% | 7.63M shares | |
| 1 holder · as of Nov 14, 2025 | |||
| Adds to | 110.14% | ||
111.56M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 110.14%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
T. Rowe Price Investment Management, Inc.Institution | 16.37% | 18.26M | as of Jun 30, 2026 |
T. Rowe Price Associates, Inc.Institution | 9.05% | 10.10M | filed May 15, 2026 |
Jupiter Topco LLCInstitution | 7.74% | 8.64M | as of Jun 30, 2026 |
Edgepoint Investment Group Inc.Institution | 7.66% | 8.54M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.86% | 7.66M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Tajinder S. Vohra | officer: Please See Remarks | −7,330 | $140.88 |
| Jul 20, 2026 | Anita Gonzales | officer: Vice President and CAO | −85 | $109.48 |
| Apr 20, 2026 | Anita Gonzales | officer: Vice President and CAO | −80 | $92.80 |
| Feb 24, 2026 | Miriame Victor | officer: Please See Remarks | −1,862 | $97.13 |
| Feb 23, 2026 | Michelle McMurry-Heath | director | −600 | $97.26 |
- Thermo Fisher Scientific
Broad overlap in research tools and specialty diagnostics
- Danaher
Platform overlap across life sciences, diagnostics, and bioprocessing
- Bio-Rad Laboratories
Two-segment peer in life-science research and clinical diagnostics
- Waters
Current owner of former BD biosciences and diagnostic overlap
- QIAGEN
Molecular diagnostics and sample-to-insight workflow peer
- Bio-Techne
Reagents, antibodies, protein analysis, and diagnostics specialist
- Illumina
Sequencing and genomics peer in omics and reproductive health
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Revvity | $144.62 | +0.72% | $16.02B | 68.4 | 25.7 | 5.5 | −1.3% |
| Thermo Fisher Scientific | $662.25 | +0.53% | $244.81B | 35.4 | 25.2 | 5.3 | +10.5% |
| Danaher | $220.87 | +2.33% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Bio-Rad Laboratories | $380.23 | +0.77% | $10.16B | 45.7 | 36.9 | 3.9 | −0.1% |
| Waters | $431.64 | +1.82% | $41.62B | 105.7 | 27.6 | 9.0 | +113.3% |
| QIAGEN | $44.06 | −1.62% | $9.24B | 23.0 | 17.7 | 4.4 | +0.3% |
| Bio-Techne | $72.55 | +0.10% | $11.35B | 62.5 | 35.0 | 9.3 | +1.3% |
| Illumina | $247.17 | +3.50% | $36.13B | 44.6 | 43.3 | 8.0 | +9.4% |
| Median | 44.6 | 27.6 | 6.0 | +5.5% |